Pfizer adds $500M to gene therapy manufacturing plant where it will hire 300 workers

Pfizer has several gene therapy programs in its pipeline and is supersizing its gene therapy manufacturing plan to support them with this facility in Sanford, North Carolina. (Pfizer)

Pfizer, which is in a race with competitors for its initial gene therapies, is shifting its production efforts into overdrive. The company will inject another $500 million into a manufacturing plant in North Carolina and says it will hire another 300 workers.

The half-billion dollar investment is on top of the $100 million it committed to the Sanford, North Carolina, project in 2017, Pfizer said today. The facility will provide backing to its gene therapy work at Pfizer's Chapel Hill and Kit Creek R&D facilities. It says the larger plant will add to both its clinical and commercial scale production capabilities for its work on potential genetic cures using recombinant adeno-associated virus vectors.. 

RELATED: Pfizer commits $100M for a gene therapies plant in North Carolina

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

“We’re excited to build this new state-of-the-art facility in Sanford because it will have the potential to help us develop novel methods to deliver transformative treatments to patients,” Angela Hwang, president of Pfizer Biopharmaceuticals Group, said in a statement

Pfizer started on the project a couple of years ago, saying it would expand an 11,000-square-foot plant in Sanford that it acquired when it bought gene therapies biotech Bamboo Therapeutics. At that time, it projected the expansion would come with about 40 jobs. The 300 hires it now intends to make will bring the Pfizer headcount to about 650 at Sanford, where workers also manufacture components for the company’s vaccine portfolio. 

RELATED: New data boost Pfizer, Sangamo hemophilia A gene therapy

Pfizer has several gene therapy programs it is shepherding through its pipeline. It and partner Sangamo Therapeutics last month shared a positive update on the durability of responses to their hemophilia A gene therapy. The sneak preview gave encouragement to those who believe it will outflank other assets including Spark Therapeutics’ SPK-8011 and BioMarin’s valrox. BioMarin this month dropped development of a lower dose of its valrox treatment in an effort to get its applications to regulators by year-end.  

Pfizer also released data this summer on its Duchenne muscular dystrophy gene therapy. That early clinical update showed that one of the first six people to receive the treatment was hospitalized with acute renal injury. The results led analysts to give the edge to a competing effort from Sarepta Therapeutics. 

Read more on

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.